Nextcure Stock Price, News & Analysis

NextCure (Nasdaq: NXTC) presented preclinical data for its investigational monoclonal antibody NC762 at the AACR Annual Meeting 2021. NC762 targets B7-H4, showing promising anti-tumor properties and inhibiting tumor growth in various cancer models. Key findings include a mechanism of action independent from T cells and NK cells, allowing for enhanced anti-tumor activity. IND-enabling studies showed a favorable safety profile and half-life of 8-10 days. NextCure plans to advance NC762 into clinical trials this quarter, aiming to expand its innovative immunomedicine pipeline.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 13 at 12:45 PM Eastern Time. The company focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. A live audio webcast will be accessible on the company's website, with a replay available for 30 days post-event.

NextCure, Inc. (Nasdaq: NXTC) reported its financial results for Q4 and full year 2020, including a net loss of $36.6 million for the year, reflecting a rise in R&D and G&A expenses. Cash reserves decreased from $334.6 million in 2019 to $283.4 million in 2020. Despite challenges from the COVID-19 pandemic, the company is advancing clinical trials for NC318, including a Phase 2 trial planned at Yale University. NextCure is also preparing to initiate trials for NC762 and anticipates sharing initial data for NC410 in the second half of 2021.

NextCure, Inc. (Nasdaq: NXTC) will host a Virtual R&D Update Event on March 4 at 5:00 p.m. ET. Interested participants can listen via a conference call or webcast through NextCure's website. The U.S. toll-free dial-in number is (877) 665-6632, or (602) 563-8471 internationally, using Conference ID 6773907. A replay will be available two hours after the event and archived for 30 days. NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer and immune-related diseases, will host a Virtual R&D Update Event on March 4 at 5:00 p.m. ET. Participants can join via conference call by calling (877) 665-6632 for US/Canada or (602) 563-8471 internationally, using Conference ID 6773907. A live webcast will be available on their website, with a replay accessible for 30 days post-event. NextCure aims to innovate treatments for patients unresponsive to existing therapies.

NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), announced the appointment of Dr. Han Myint as chief medical officer. Dr. Myint will lead the clinical development of key products including NC318 and NC410. His previous roles include senior positions at Celgene and NexImmune, where he contributed to multiple FDA-approved products. NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its FIND-IO™ platform.

NextCure, Inc. (Nasdaq: NXTC) announced updates on the clinical trial of NC318, an immunomedicine targeting Siglec15 for cancer treatment. The company is refining its trial plans to better identify S15-positive patients. Notably, two patients have shown long-term responses, remaining in the trial for over 104 weeks. A confirmed partial response in head and neck cancer supports progression in its trial phases. While NC318 is generally well-tolerated, the company will adjust its strategy for patient selection to improve outcomes.

NextCure, Inc. (Nasdaq: NXTC), a biopharmaceutical company focused on developing immunomedicines for cancer and immune-related diseases, will participate in a fireside chat at the Piper Sandler Virtual Healthcare Conference on December 1. The chat will feature a pre-recorded audio webcast accessible on their investors' section of the website, www.nextcure.com, and archived for 30 days. NextCure uses its proprietary FIND-IO™ platform to discover new treatments for patients unresponsive to existing therapies.

NextCure, Inc. (Nasdaq: NXTC) reported its third quarter 2020 financial results, highlighting ongoing clinical trials for NC318 and NC410. The company has $291.2 million in cash as of September 30, 2020, down from $334.6 million at the end of 2019, largely due to operational costs. R&D expenses increased to $12.7 million from $8.7 million year-over-year, while G&A expenses rose to $4.7 million from $2.6 million. Notably, there was no revenue this quarter, down from $1.6 million in Q3 2019, resulting in a net loss of $16.4 million, compared to $8.4 million last year.